ARLINGTON, VA, January 6, 2011 – BioInformatics, LLC announces the release of their newest market report:
Genomic Technologies: Market Insights for Life Science Suppliers (#10-005)
This report is for life science suppliers who want to respond in a timely fashion to the rapidly changing market for genomic analysis products. In this study, BioInformatics LLC quantifies and characterizes the market for genetic analysis including those products used for genome-wide association studies (GWAS), copy number variation (CNV) analysis, genotyping and techniques such as microarrays, sequencing and real-time PCR.
Survey respondents indicate planned lab expenditures by vendor. The following suppliers were provided as some of the choices in the survey:
Agilent Technologies (NYSE: A)
Affymetrix (NASDAQ: AFFX)
Beckman Coulter (NYSE: BEC)
BD Biosciences (NYSE: BDX)
Bioneer
Bio-Rad (NYSE: BIO)
BioTrove
Cepheid (NASDAQ: CPHD)
Eppendorf
GE Healthcare (NYSE: GE)
Helicos Bioscience (NASDAQ: HLCS)
Idaho Technology, Inc.
Illumina (NASDAQ: ILMN)
Li-Cor Biosciences
Life Technologies (NasdaqGS: LIFE))
Luminex (NASDAQ: LMNX)
Qiagen (NasdaqGS: QGEN)
Roche Applied Science
Sequenom (NASDAQ: SQNM)
Stratagene
Techne (NASDAQ: TECH)
“In this study, we look at genetic analysis in current life science laboratories, the techniques and applications used, satisfaction and unmet needs with respect to current product offerings, budgets and predicted growth and future needs among life scientists,” states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. Dr. Zemlo adds that “The information presented in this report will provide life science suppliers with information they can use to better meet their customers’ needs as the field of genetic analysis continues to expand in new directions.”
To learn more about these reports, a complimentary Executive Summary is available at:
http://www.gene2drug.com/index.php?page=reports&id=211
ABOUT BIOINFORMATICS, LLC
BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 50,000 life scientists, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact:
Mary Follin Manager, Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 703.778.3080 x13 (phone) m.follin@gene2drug.com http://www.gene2drug.com/
